Published date: Jun 30 2022

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 17 (2022), Issue No. 2

Pages: 263–278

DOI: 10.18502/sjms.v17i2.11460

Hyder Osman Mirghanis.hyder63@hotmail.comAssociate Professor of Internal Medicine and Endocrine, Faculty of Medicine, University of Tabuk, Saudi Arabia

Albaraa AltowigriAssistant Professor of Orthopedics, Faculty of Medicine, University of Tabuk, Saudi Arabia

Background: Osteoporosis is a common morbid and mortal disease; thyroid-stimulating hormone (TSH) suppression is the state-of-the-art for postoperative differentiated thyroid carcinoma (DTC). However, its association with osteoporosis remains controversial. The current meta-analysis assessed the relationship between TSH suppressive therapy and osteoporosis among patients with DTC.

Methods: We systematically searched PubMed, Cochrane Library, EBSCO, and the first 100 articles in Google Scholar for relevant articles published in English during the period from 2008 to November 2020. The keywords differentiated thyroid cancer, TSH suppression, osteoporosis, low bone mineral density, osteopenia; fracture risk, disturbed bone micro-architecture, bone loss, and trabecular bone were used. One hundred and eighty-four articles were retrieved; of them, fourteen were eligible and met the inclusion and exclusion criteria. The RevMan system was used for data analysis.

Results: We included 36 cohorts from 15 studies, the studies showed higher osteoporosis and osteopenia among TSH-suppressed women, odd ratio, 2.64, 1.48– 4.68 and 2.23, 0.33–14.96, respectively. High heterogeneity was observed, I² = 68% and 96%, respectively). The sub-analysis showed a lower bone mineral density among postmenopausal women at both femoral neck and lumbar spines, odds ratio, –0.02, –0.07 to 0.04, and –0.03, –0.06 to 0.01, I2 for heterogeneity, 69%, and 51% in contrast to men and premenopausal women who showed normal or higher bone density.

Conclusion: TSH suppression for DTC was associated with osteoporosis and osteopenia among postmenopausal women but not premenopausal women or men. Studies focusing on trabecular bone scores are needed.

Keywords: TSH suppression, differentiated thyroid carcinoma, osteoporosis

[1] Farahati, J., Mäder, U., Gilman, E., et al. (2019). Changing trends of incidence and prognosis of thyroid carcinoma. Nuklearmedizin, vol. 58, no. 2, pp. 86–92.

[2] Sekkath Veedu, J., Wang, K., Lei, F., et al. (2018). Trends in thyroid cancer incidence in India. Journal of Clinical Oncology, vol. 36, no. 15, pp. 18095–18095.

[3] Krishnaja, K. S., Rallapeta, R. P., Shaik, M., et al. (2019). Papillary carcinoma thyroid metastases presenting as thyrotoxicosis post thyroidectomy - A case report. Indian Journal of Nuclear Medicine, vol. 34, no. 2, pp.134–136.

[4] Papaleontiou, M., Chen, D. W., Banerjee, M., et al. (2021). Thyrotropin suppression for papillary thyroid cancer: A physician survey study. Thyroid, vol. 31, no. 9, pp. 1383–1390.

[5] Soydal, Ç., Özkan, E., Nak, D., et al. (2019). Risk factors for predicting osteoporosis in patients who receive thyrotropin suppressive levothyroxine treatment for differentiated thyroid carcinoma. Molecular Imaging and Radionuclide Therapy, vol. 28, no. 2, pp. 69–75.

[6] Bai, Y., Huo, Y., Yu, F., et al. (2017). Effect of hypoparathyroid on bone mineral density of lumber spine in postmenopausal women with differentiated thyroid cancinoma. Hellenic Journal of Nuclear Medicine, vol. 20, pp.7–13.

[7] Freudenthal, B. and Williams, G. R. (2017). Thyroid stimulating hormone suppression in the long-term follow-up of differentiated thyroid cancer. Clinical Oncology (Royal College of Radiologists), vol. 29, no.5, pp. 325–328.

[8] Ku, E. J., Yoo, W. S., Lee, E. K., et al. (2021). Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, vol. 106, no. 12, pp. 3655–3667.

[9] Müller, C. G., Bayley, T. A., Harrison, J. E., et al. (1995). Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid, vol. 5, no. 2, pp. 81–87.

[10] Wang, L. Y., Smith, A. W., Palmer, F. L., et al. (2015). Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediaterisk patients with differentiated thyroid carcinoma. Thyroid, vol. 25, no. 3, pp. 300– 307.

[11] de Melo, T. G., da Assumpção, L. V., Santos Ade, O., et al. (2015). Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma. Thyroid Research, vol. 2, no. 8, p. 7.

[12] Mazziotti, G., Formenti, A. M., Frara, S., et al. (2018). High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 3, pp. 956–964.

[13] Zhang, P., Xi, H., and Yan, R. (2018). Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma. OncoTargets and Therapy, vol. 9, no. 11, pp. 6687–6692.

[14] Vera, L., Gay, S., Campomenosi, C., et al. (2016). Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. Endokrynologia Polska, vol. 67, no. 4, pp. 350–358.

[15] De Mingo Dominguez, M. L., Guadalix Iglesias, S., Martin-Arriscado Arroba, C., et al. (2018). Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. Endocrine, vol. 62, no. 1, pp. 166–173.

[16] Franklyn, J. A., Betteridge, J., Daykin, J., et al. (1992). Long-term thyroxine treatment and bone mineral density. Lancet, vol. 340, no. 8810, pp. 9–13.

[17] Fujiyama, K., Kiriyama, T., Ito, M., et al. (1995). Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. Thyroid, vol. 5, no. 1, pp. 13–17.

[18] Kung, A. W., Lorentz, T., and Tam, S. C. (1993). Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clinical Endocrinology, vol. 39, no. 5, pp. 535–540.

[19] Moon, J. H., Jung, K. Y., Kim, K. M., et al. (2016). The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma. Bone, vol. 83, pp. 104–110.

[20] Reverter, J. L., Holgado, S., Alonso, N., et al. (2005). Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocrine-Related Cancer, vol. 12, no. 4, pp. 973–981.

[21] Tournis, S., Antoniou, J. D., Liakou, C. G., et al. (2015). Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clinical Endocrinology, vol. 82, no. 2, pp. 197–204.

[22] Goerres, G., Theiler, R., and Müller-Brand, J. (1998). Interfemur variation of bone mineral density in patients receiving high-dose thyroxin therapy. Calcified Tissue International, vol. 63, no. 2, pp. 98–101.

[23] Rozenberg, S., Bruyère, O., Bergmann, P., et al. (2020). How to manage osteoporosis before the age of 50. Maturitas, vol. 138, pp. 14–25.

[24] Langdahl, B. L. (2017). Osteoporosis in premenopausal women. Current Opinion in Rheumatology, vol. 29, no. 4, pp. 410–415.

[25] Ku, E. J., Yoo, W. S., Lee, E. K., et al. (2021). Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, vol. 106, no. 12, pp. 3655–3667.

[26] Kwak, D., Ha, J., Won, Y., et al. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open, vol. 11, no. 5, p. 043007.

[27] Haymart, M. R., Reyes-Gastelum, D., Caoili, E., et al. (2020). The relationship between imaging and thyroid cancer diagnosis and survival. Oncologist, vol. 25, no. 9, pp. 765–771.

[28] Papaleontiou, M., Banerjee, M., Reyes-Gastelum, D., et al. (2019). Risk of osteoporosis and fractures in patients with thyroid cancer: A case-control study in U.S. veterans. Oncologist, vol. 24, no. 9, pp. 1166–1173.

[29] Biondi, B. and Cooper, D. S. (2010). Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid, vol. 20, no. 2, pp. 135–146.

[30] Soydal, Ç., Özkan, E., Nak, D., et al. (2019). Risk factors for predicting osteoporosis in patients who receive thyrotropin suppressive levothyroxine treatment for differentiated thyroid carcinoma. Molecular Imaging And Radionuclide Therapy, vol. 28, no. 2, pp. 69–75.

[31] Hawkins Carranza, F., Guadalix Iglesias, S., Luisa De Mingo Domínguez, M., et al. (2020).Trabecular bone deterioration in differentiated thyroid cancer: Impact of longterm TSH suppressive therapy. Cancer Medicine, vol. 9, no. 16, pp. 5746–5755.